These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19395904)

  • 1. Predictors of treatment response in pediatric obsessive-compulsive disorder.
    Grados MA; Ginsburg GS; Drake KL; Kingery JN
    J Am Acad Child Adolesc Psychiatry; 2009 May; 48(5):573-574. PubMed ID: 19395904
    [No Abstract]   [Full Text] [Related]  

  • 2. Reactivity of serotonin in whole blood.
    Mulder EJ; Anderson GM; Kema IP; Minderaa RB
    Biol Psychiatry; 2002 Feb; 51(3):266-8. PubMed ID: 11839371
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
    Varigonda AL; Jakubovski E; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder.
    Humble M; Bejerot S; Bergqvist PB; Bengtsson F
    Biol Psychiatry; 2001 Feb; 49(4):360-8. PubMed ID: 11239907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamotrigine Augmentation in Treatment-Resistant Pediatric Obsessive-Compulsive Disorder with a 16 Month Follow-up.
    Naguy A; Alamiri B; Al-Khadhari S; Francis K
    J Child Adolesc Psychopharmacol; 2016 Oct; 26(8):769-772. PubMed ID: 26465832
    [No Abstract]   [Full Text] [Related]  

  • 8. The first Japanese pediatric case of obsessive-compulsive disorder who responded to a selective serotonin re-uptake inhibitor.
    Furusho J; Kubagawa T; Saitoh N; Matsuzaki K; Yamakawa H; Iikura Y
    Pediatr Int; 2000 Aug; 42(4):451-2. PubMed ID: 10986886
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Drug Ther Bull; 1995 Jun; 33(6):47-8. PubMed ID: 7587998
    [No Abstract]   [Full Text] [Related]  

  • 10. Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder.
    Corregiari FM; Bernik M; Cordeiro Q; Vallada H
    Clinics (Sao Paulo); 2012; 67(4):335-40. PubMed ID: 22522758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of clomipramine in obsessive-compulsive disorder.
    Howland RH
    Anxiety; 1996; 2(1):56-7. PubMed ID: 9160602
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictors of response to serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Hazari N; Narayanaswamy JC; Arumugham SS
    Expert Rev Neurother; 2016 Oct; 16(10):1175-91. PubMed ID: 27282021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder.
    Owley T; Owley S; Leventhal B; Cook EH
    J Child Adolesc Psychopharmacol; 2002; 12(2):165-71. PubMed ID: 12188985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sertraline and obsessive compulsive disorder: new indication. Limited assessment.
    Prescrire Int; 2000 Aug; 9(48):112-3. PubMed ID: 11067720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.
    Ravindran AV; Lapierre YD; Anisman H
    Can J Psychiatry; 1999 Oct; 44(8):805-7. PubMed ID: 10566112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors.
    Vythilingum B; Cartwright C; Hollander E
    Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S7-13. PubMed ID: 11110014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venlafaxine for treatment of obsessive-compulsive disorder.
    Ananth J; Burgoyne K; Smith M; Swartz R
    Am J Psychiatry; 1995 Dec; 152(12):1832. PubMed ID: 8526258
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of obsessive-compulsive disorder with venlafaxine.
    Grossman R; Hollander E
    Am J Psychiatry; 1996 Apr; 153(4):576-7. PubMed ID: 8599411
    [No Abstract]   [Full Text] [Related]  

  • 19. Obsessive-compulsive disorder due to neuroacanthocytosis treated with citalopram. A case report.
    Habermeyer B; Fuhr P; Hiss B; Alber C; Müller-Spahn F
    Pharmacopsychiatry; 2006 Sep; 39(5):193-4. PubMed ID: 16944412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.